DEVELOPMENT AND EVALUATION OF MUCOADHESIVE NANOGEL OF NEVIRAPINE FOR VAGINAL APPLICATION
Objectives: The main objective of this study was to develop and evaluate Nevirapine nanoparticle loaded mucoadhesive gel (NVP-Np mucoadhesive gel) for vaginal application for the treatment of HIV infection.
Methods: NVP loaded nanoparticles were prepared by salting out method followed by incorporation in different gel bases to produce NVP-Np mucoadhesive gel The prepared gels were evaluated for their physicochemical parameters, rheological characteristics, mucoadhesion, in-vitro drug release and ex-vivo permeation of drug across porcine vaginal mucosa.
Results: The result of FT-IR and DSC study confirmed the absence of incompatibility of NVP with excipients used in the formulations. The particle size of the prepared NVP-Np was found to be 243.8 ± 3.15 nm, a polydispersity index (PI) of 0.787± 0.002 and zeta potential value -17.12 mV, which revealed the stability of nanoparticles. All the formulations showed good homogeneity, spreadability, physical appearance and content uniformity. The pH of the mucoadhesive gel formulations was in the range of 3.70 ± 0.03 to 4.56 ± 0.02, which lies in the normal pH range of the vaginal fluid. The cumulative amounts permeated at 6 h were 832.23 ± 63.45 μg/cm2 , 592.13 ± 82.55 μg/cm2 and 941.32 ± 81.10 μg/cm2 from F1(1% Chitosan), F2(1% Carbopol 974P) and F3 (1% HPMC K100M ) respectively. A linear relationship [r2 > 0.9 (0.97 n 0.99)] was observed between the percentage cumulative amount permeated and time, indicating zero order kinetics.
Conclusion: In conclusion, NVP-Np mucoadhesive gel was prepared successfully using salting out followed by a homogenization technique for vaginal application of NVP for the prophylaxis of HIV infection.
2. Kallings LO. The first postmodern pandemic: 25 y of HIV/AIDS. J Intern Med 2008;263:218–43.
3. Antimisiaris SG, Mourtas S. Recent advances on anti-HIV vaginal delivery system development. Adv Drug Delivery Rev 2015;92:1-23.
4. Ensign LM, Cone R, Hanes J. Nanoparticle-based drug delivery to the vagina: a review. J Controlled Release 2014;190:500-14.
5. Mallikarjunarao P, Kumar MY, Kumar KM, Prathyusha S, lavanya D. formulation and in vitro evaluation of nevirapine extended release matrix tablets. Int J Res Dev Pharm Lett Sci 2014;3:1054-65.
6. Vyas SP, Khar RK. Targeted and controlled drug delivery novel carrier system. 1st ed. New Delhi: CBS Publishers and Distributors Pvt. Ltd; 2002.
7. Lopez Leon T, Carvalho ELS, Seijo B, Ortega Vinuesa JL, Bastos Gonalez D. Physicochemical characterization of chitosan nanoparticles: electrokinetic and stability behaviour. J Colloid Interface Sci 2005;283:344-6.
8. Tao Z, Timothy FS, Bi-Botti CY. pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission. Eur J Pharm Biopharm 2011;79:526-36.
9. Ahmed AB, Nath LK. Drug-excipient compatibility studies of nicorandil in controlled release floating tablet. Int J Pharm Pharm Sci 2014;6:468-75.
10. Deshkar S, Sonkamble K, Mahore JG. Formulation and optimization of nanosuspension for improving solubility and dissolution of gemfibrozil. Asian J Pharm Clin Res 2019;12:157-63.
11. Tao Z, Timothy FS, Bi-Botti CY. pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission. Eur J Pharm Biopharm 2011;79:526-36.
12. Ahmed AB, Ahmed R, Sengupta. Formulation and in vitro/ex-vivo characterizations of microemulsion-based hydrogel formulation of aceclofenac for topical application. Asian J Pharm Clin Res 2016;9(Suppl 1):87-91.
13. Sakharee SS, Yadav AV, Jadhav PD. Design, development and characterization of mucoadhesive gastro spheres of carvedilol. Int J Appl Pharm 2016;8:1-16.
14. Singh G, Rawat N, Singh K, Sarwal A, Sinha VR. Potential of an antidepressant intranasal mucoadhesive microemulsion. Int J Pharm Pharm Sci 2018;10:125-32.
15. Senyigit ZA, Karavana SY, Erac B, Gursel O, Limoncu MH, Baloglu E. Evaluation of chitosan-based vaginal bioadhesive gel formulations for antifungal drugs. Acta Pharm 2014;64:139-56.
16. Keshary PR, Cheien YW. Mechanism of transdermal controlled nitroglycerin administration. Part 2. Assessment of rate controlling steps. Drug Dev Ind Pharm 1984;10:1663.
17. Eyk VAD, Bijl VP. Porcine vaginal mucosa as an in vitro permeability model for human vaginal mucosa. Int J Pharm 2005;305:105-11.
18. Alotaibi FO, Mustafa GM, Ahuja A. Enhanced anti-inflammatory potential of Nigella sativa in topical nanoformulation. Int J Pharm Pharm Sci 2018;10:41-51.
19. Martin Villenaa MJ, Fernandez Campos F, Calpena Campmany AC, Bozal de Febrerc N, Ruiz Martineza MA, Clares Naverosa B. Novel microparticulate systems for the vaginal delivery of nystatin: development and characterization. Carbohydr Polym 2013;94:1-11.
20. Subramanian N, Ghosal SK, Moulik SP. Enhanced in vitro percutaneous absorption and in vivo anti-inflammatory effect of a selective cyclooxygenase inhibitor using microemulsion. Drug Dev Ind Pharm 2005;31:405-16.
21. Barakat NS. Evaluation of glycofurol-based gel as a new vehicle for topical application of naproxen. AAPS Pharm Sci Tech 2010;11:1138-46.
22. Rampino A, Borgogna M, Blasi P, Bellich B, Cesaroa A. Chitosan nanoparticles: preparation, size evolution and stability. Int J Pharm 2013;455:219-28.
23. Jaiswal J, Gupta SK, Kreuter J. Preparation of biodegradable cyclosporine nanoparticles by a high-pressure emulsification-solvent evaporation process. J Controlled Release 2004;96:169-78.
24. Honary S, Zahir F. Effect of zeta potential on the properties of nano-drug delivery systems-a review (Part 1). Trop J Pharm Res 2013;12:255-64.
This work is licensed under a Creative Commons Attribution 4.0 International License.